The core-aldehyde 9-oxononanoyl cholesterol increases the level of transforming growth factorβ1-specific receptors on promonocytic U937 cell membranes

Aging Cell

Volumn 8, Issue 2, 2009, Pages 77-87

  Gargiulo, Simona ^a   Gamba, Paola ^a   Sottero, Barbara ^a   Biasi, Fiorella ^a   Chiarpotto, Elena ^a   Serviddio, Gaetano ^b   Vendemiale, Gianluigi ^c   Poli, Giuseppe ^a   Leonarduzzi, Gabriella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

9 oxononanoyl cholesterol; Atherosclerosis; Fibrotic plaque; Mitogen activated protein kinases; TGF 1; TGF 1 receptors

Indexed keywords

CHOLESTEROL; CORE ALDEHYDE 9 OXONONANOYL CHOLESTEROL; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; AUTOCRINE EFFECT; CELL AGING; CELL MEMBRANE; CELL STIMULATION; CELL STRAIN U937; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION;

ATHEROSCLEROSIS; AUTOCRINE COMMUNICATION; BENZAMIDES; CELL LINE; CELL MEMBRANE; CHOLESTEROL; DIOXOLES; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MONOCYTE-MACROPHAGE PRECURSOR CELLS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 63749107262     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/j.1474-9726.2009.00454.x     Document Type: Article

References (53)

1. Blanco FJ, Grande MT, Langa C, Oujo B, Velasco S, Rodriguez-Barbero A, Perez-Gomez E, Quintanilla M, Lopez-Novoa JM, Bernabeu C (2008) S-Endoglin expression is induced in senescent endothelial cells and contributes to vascular pathology. Circ. Res. 103, 1383-1392.
2. Blobe GC, Schiemann WB, Lodish HF (2000) Role of transforming growth factor-β in human disease. N. Engl. J. Med. 342, 1350-1358.
3. Bobik A (2006) Transforming growth factor-βs and vascular disorders. Arterioscler. Thromb. Vasc. Biol. 26, 1712-1720.
4. Bobik A, Agrotis A, Kanellakis P, Dilley R, Krushinsky A, Smirnov V, Tararak E, Condron M, Kostolias G (1999) Distinct patterns of transforming growth factor-β isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-β in fibrofatty lesion development. Circulation 99, 2883-2891.
5. Bochkov VN (2007) Inflammatory profile of oxidized phospholipids. Thromb. Haemost. 97, 348-354.
6. Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, Hofer E, Binder BR, Leitinger N (2002) Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca (++)/NFAT. Blood 99, 199-206.
7. Boechzelt H, Karten B, Abuja PM, Slatter W, Mittelbach M (1998) Synthesis of 9-oxononanoyl cholesterol by ozonization. J. Lipid Res. 39, 1503-1507.
8. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
9. Carlson ME, Silva HS, Conboy IM (2008) Aging of signal transduction pathways, and pathology. Exp. Cell Res. 314, 1951-1961.
10. Cipollone F, Fazia M, Mincione G, Iezzi A, Pini B, Cuccurullo C, Ucchino S, Spigonardo F, Di Nisio M, Cuccurullo F, Mezzetti A, Porreca E (2004) Increased expression of transforming growth factor-β1 as a stabilizing factor in human atherosclerotic plaques. Stroke 35, 2253-2257.
11. Deigner HP, Hermetter A (2008) Oxidized phospholipids: Emerging lipid mediators in pathophysiology. Curr. Opin. Lipidol. 19, 289-294.
12. Gojova A, Brun V, Esposito B, Cottrez F, Gourdy P, Ardouin P, Tedgui A, Mallat Z, Groux H (2003) Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood 102, 4052-4058.
13. Grainger DJ (2004) Transforming growth factor β and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler. Thromb. Vasc. Biol. 24, 399-404.
14. Grainger DJ (2007) TGF-β and atherosclerosis in man. Cardiovasc. Res. 74, 213-222.
15. Hoppe G, Ravandi A, Herrera D, Kuksis A, Hoff HF (1997) Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesion. J. Lipid Res. 38, 1347-1360.
16. Huber J, Boechzelt H, Karten B, Surboeck M, Bochkov VN, Binder BR, Sattler W, Leitinger N (2002) Oxidized cholesteryl linoleates stimulate endothelial cells to bind monocytes via the extracellular signal-regulated kinase 1/2 pathway. Arterioscler. Thromb. Vasc. Biol. 22, 581-586.
17. Ihn H (2002) Pathogenesis of fibrosis: Role of TGF-β and CTGF. Curr. Opin. Rheumatol. 14, 681-685.
18. Ihn H (2008) Autocrine TGF-β signaling in the pathogenesis of systemic sclerosis. J. Dermatol. Sci. 49, 103-113.
19. Ito T, Sawada R, Fujiwara Y, Seyama Y, Tsuchiya T (2007) FGF-2 suppresses cellular senescence of human mesenchymal stem cells by down-regulation of TGF-β2. Biochem. Biophys. Res. Commun. 359, 108-114.
20. Kamido H, Kuksis A, Marai L, Myher JJ (1992) Identification of cholesterol-bound aldehydes in copper-oxidized low density lipoprotein. FEBS Lett. 304, 269-272.
21. Kamido H, Kuksis A, Marai L, Myher JJ (1993) Identification of core-aldehydes among in.vitro peroxidation products of cholesteryl esters. Lipids 28, 331-336.
22. Kamido H, Kuksis A, Marai L, Myher JJ (1995) Lipid ester-bound aldehydes among copper-catalyzed peroxidation products of human plasma lipoproteins. J. Lipid Res. 36, 1876-1886.
23. Karten B, Boechzelt H, Abuja PM, Mittelbach M, Oettl K, Sattler W (1998) Femtomole analysis of 9-oxononanoyl cholesterol by high performance liquid chromatography. J. Lipid Res. 39, 1508-1519.
24. Kawai Y, Saito A, Shibata N, Kobayashi M, Yamada S, Osawa T, Uchida K (2003) Covalent binding of oxidized cholesteryl esters to protein. J. Biol. Chem. 278, 21040-21049.
25. Kawai Y, Miyoshi M, Moon JH, Terao J (2006) Detection of cholesteryl ester hydroperoxide isomers using gas chromatography-mass spectrometry combined with thin-layer chromatography blotting. Anal. Biochem. 360, 130-137.
26. Leask A, Abraham DJ (2004) TGF-β signaling and the fibrotic response. FASEB J. 18, 816-827.
27. Leitinger N (2003) Cholesteryl ester oxidation products in atherosclerosis. Mol. Aspects Med. 24, 239-250.
28. Leitinger N (2005) Oxidized phospholipids as triggers of inflammation in atherosclerosis. Mol. Nutr. Food Res. 49, 1063-1071.
29. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G (1997) The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: A link between oxidative injury and fibrosclerosis. FASEB J. 11, 851-857.
30. Leonarduzzi G, Sevanian A, Sottero B, Arkan MC, Biasi F, Chiarpotto E, Basaga H, Poli G (2001) Up-regulation of the fibrogenic cytokine TGF-β1 by oxysterols: A mechanistic link between cholesterol and atherosclerosis. FASEB J. 15, 1619-1621.
31. Leonarduzzi G, Sottero B, Poli G (2002) Oxidized products of cholesterol: Dietary and metabolic origin, and proatherosclerotic effects. J. Nutr. Biochem. 13, 700-710.
32. Leonarduzzi G, Chiarpotto E, Biasi F, Poli G (2005a) 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol. Nutr. Food Res. 49, 1044-1049.
33. Leonarduzzi G, Gamba P, Sottero B, Kadl A, Robbesyn F, Calogero RA, Biasi F, Chiarpotto E, Leitinger N, Sevanian A, Poli G (2005b) Oxysterol-induced up-regulation of MCP-1 expression and synthesis in macrophage cells. Free Radic Biol. Med. 39, 1152-1161.
34. Leonarduzzi G, Gamba P, Gargiulo S, Sottero B, Kadl A, Biasi F, Chiarpotto E, Leitinger N, Vendemiale G, Serviddio G, Poli G (2008) Oxidation as a crucial reaction for cholesterol to induce tissue degeneration: CD36 overexpression in human promonocytic cells treated with a biologically relevant oxysterol mixture. Aging Cell 7, 375-382.
35. Libby P (2002) Inflammation in atherosclerosis. Nature 420, 868-874.
36. -ΔΔC T method. Methods 25, 402-408.
37. Lusis AJ (2000) Atherosclerosis. Nature 407, 233-241.
38. Lutgens E, Gijbels M, Smook M, Heeringa P, Gotwals P, Koteliansky VE, Daemen MJAP (2002) Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22, 975-982.
39. Mallat Z, Gojova A, Marchiol-Fournigault C, Esposito B, Kamaté C, Merval R, Fradelizi D, Tedgui A (2001) Inhibition of transforming growth factor-β signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89, 930-934.
40. Natarajan E, Omobono JD, 2nd Guo Z, Hopkinson S, Lazar AJF, Brenn T, Jones JC, Rheinwald JG (2006) A keratinocyte hypermotility/growth-arrest response involving laminin 5 and p16INK4A activated in wound healing and senescence. Am. J. Pathol. 168, 1821-1837.
41. Poli G, Schaur RJ, Siems WG, Leonarduzzi G (2008) 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Med. Res. Rev. 28, 569-631.
42. Robertson A-KL, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK (2003) Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112, 1342-1350.
43. Ross R (1999) Atherosclerosis is an inflammatory disease. Am. Heart J. 138, S419-S420.
44. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-β signaling in vascular fibrosis. Cardiovasc. Res. 74, 196-206.
45. Schroepfer GJ Jr (2000) Oxysterols: Modulators of cholesterol metabolism and other processes. Physiol. Rev. 80, 361-554.
46. Schuster N, Krieglstein K (2002) Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res. 307, 1-14.
47. Shi Y, Massagué J (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 113, 685-700.
48. Sottero B, Gamba P, Longhi M, Robbesyn F, Abuja PM, Schaur RJ, Poli G, Leonarduzzi G (2005) Expression and synthesis of TGFβ1 is induced in macrophages by 9-oxononanoyl cholesterol, a major cholesteryl ester oxidation product. Biofactors 24, 209-216.
49. Steinberg D (2002) Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime. Nature 8, 1211-1217.
50. Upston JM, Niu K, Brown AJ, Mashima R, Wang H, Senthilmohan R, Kettle AJ, Dean RT, Stocker R (2002) Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am. J. Pathol. 160, 701-710.
51. Verrecchia F, Mauviel A (2002) Control of connective tissue gene expression by TGFβ: Role of Smad proteins in fibrosis. Curr. Rheumatol. Rep. 4, 143-149.
52. Verrecchia F, Mauviel A (2007) Transforming growth factor-β and fibrosis. World J. Gastroenterol. 13, 3056-3062.
53. Yun MR, Im DS, Lee SJ, Woo JW, Hong KW, Bae SS, Kim CD (2008) 4-Hydroxynonenal contributes to macrophage foam cell formation through increased expression of class A scavenger receptor at the level of translation. Free Radic. Biol. Med. 45, 177-183.